Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations

D Moreno-Pérez1, F J Alvarez García, J Aristegui Fernández

  • 1Spanish Association of Pediatrics Vaccines Advisory Committee, Spain. dmp.malaga@gmail.com

Insights

The Spanish Association of Pediatrics

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • The Advisory Committee on Vaccines (CAV-AEP) annually updates immunization schedules.
  • Schedules consider epidemiological data, vaccine effectiveness, and efficiency.
  • Vaccinations are categorized as routine, recommended, or for risk groups.

Purpose of the Study:

  • To present the updated annual immunization schedule from the CAV-AEP.
  • To outline key changes and recommendations for childhood vaccinations in Spain.
  • To emphasize the importance of achieving a unified national immunization schedule.

Main Methods:

  • Annual review of epidemiological data and vaccine evidence.
  • Categorization of vaccines based on recommendation levels (routine, recommended, risk group).
  • Analysis of current epidemiological trends to inform schedule adjustments.

Main Results:

  • MMR and varicella vaccines: first dose at 12 months (12-15 months), second dose at 2-3 years.
  • Tdap vaccine: first dose at 4-6 years, second dose at 11-14 years.
  • Recommendations for increased HPV vaccination coverage, routine pneumococcal, universal varicella, and rotavirus vaccination.
  • Emphasis on vaccinating at-risk groups for influenza and hepatitis A, and catch-up immunizations.

Conclusions:

  • The updated schedule incorporates new epidemiological insights and vaccine data.
  • Key changes include adjusted timings for MMR, varicella, and Tdap vaccines.
  • Continued emphasis on universal vaccination for preventable diseases and addressing vaccination gaps.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...